Fiscal Third Quarters Ended (Dollars in Millions) October2, 2016 September27, 2015 Percent Change Consumer (1) $ 679 811 (16.3 )% Pharmaceutical (2) 3,309 2,732 21.1 Medical Devices (3) 1,526 835 82.8 Segments operating profit 5,514 4,378 25.9 Less: Expense not allocated to segments (4) 233 256 Worldwide income before tax $ 5,281 4,122 28.1 % Fiscal Nine Months Ended (Dollars in Millions) October2, 2016 September27, 2015 Percent Change Consumer (1) $ 1,816 1,772 2.5 % Pharmaceutical (2) 10,340 9,816 5.3 Medical Devices (3) 4,041 4,640 (12.9 ) Segments operating profit 16,197 16,228 (0.2 ) Less: Expense not allocated to segments (4) 718 790 Worldwide income before taxes $ 15,479 15,438 0.3 % (1) Includes a gain of $229 million from the divestiture of the SPLENDA  brand recorded in the fiscal third quarter and fiscal nine months of 2015. (2) Includes litigation expense of $136 million recorded in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA  (tapentadol), NUCYNTA  ER (tapentadol extended-release tablets), and NUCYNTA  (tapentadol) oral solution. Includes a positive adjustment of $513 million and $462 million to previous reserve estimates in the fiscal nine months of 2016 and 2015, respectively. (3) Includes a restructuring related charge of $109 million and $387 million in the fiscal third quarter and fiscal nine months of 2016, respectively. Includes litigation expense of $55 million and $731 million recorded in the fiscal third quarter and fiscal nine months of 2016, respectively. Includes litigation expense of $409 million in the fiscal third quarter of 2015. Includes a $346 million intangible asset write-down related to Acclarent recorded in the fiscal third quarter and fiscal nine months of 2015. The fiscal nine months of 2015 included $148 million for costs associated with the DePuy ASR TM Hip program. (4) Amounts not allocated to segments include interest income/expense and ge